The US Food and Drug Administration issued 11 warning letters yesterday to companies that have non NDI ingredients in their products. Eight of the warning letters concerned DMHA, with the other three concerned phenibut.
The Food and Drug Administration announced a new ‘rapid communication tool,’ called the Dietary Ingredient Advisory List. Trade groups and industry experts applauded the effort, but many opined that this step still has much left to be desired in terms...
As sports nutrition becomes increasingly of interest to mainstream consumers, is this all one great opportunity for brands or is this mass orientation diluting the messages and alienating the core consumers?
CBD firm Bod Australia has embarked on a first-of-its-kind clinical trial on medical cannabis for Tourette syndrome patients, while continuing to expand its supplements business in countries with a more conducive regulatory environment than its home market.
Probiotic and prebiotic products will be the fastest-growing functional foods in Latin America over the next seven years, fueled by consumer desire for general health and wellbeing benefits, says Grand View Research.